These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2527 related items for PubMed ID: 16032728

  • 1. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V, Red de Investigación en SIDA.
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [Abstract] [Full Text] [Related]

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Sep; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 3. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C, Martín-Carbonero L, Gallego O, Corral A, González-Lahoz J, Soriano V.
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [Abstract] [Full Text] [Related]

  • 4. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [Abstract] [Full Text] [Related]

  • 5. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveira RH, Sill AM, DeVico A, Tanuri A.
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.
    de Mendoza C, Rodriguez C, García F, Eiros JM, Ruíz L, Caballero E, Aguilera A, Leiva P, Colomina J, Gutierrez F, del Romero J, Aguero J, Soriano V, Spanish HIV Seroconverter Study Group.
    J Antimicrob Chemother; 2007 Apr; 59(4):698-704. PubMed ID: 17327295
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T, Nagappan V, Cinti S, Wei W, Kazanjian P.
    Clin Infect Dis; 2007 Oct 15; 45(8):1085-92. PubMed ID: 17879930
    [Abstract] [Full Text] [Related]

  • 12. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD, EuroSIDA Study Group.
    Antivir Ther; 2010 Oct 15; 15(4):563-70. PubMed ID: 20587849
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.
    J Med Virol; 2007 Feb 15; 79(2):105-10. PubMed ID: 17177308
    [Abstract] [Full Text] [Related]

  • 19. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Feb 15; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 20. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R, Jørgensen LB, Møller BK, Black FT, Kjems J, Obel N.
    J Clin Virol; 2005 Dec 15; 34(4):257-67. PubMed ID: 16286049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 127.